Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia
Table 6
Risk for malignant tumors.
Malignancy
Cases (adrenocortical tumor)
Controls (normal adrenal)
OR (95% CI)
AOR (95% CI)
Gastrointestinal cancer
22 (5.5%)
29 (7.3%)
0.74 (0.42, 1.32)
0.84 (0.42, 1.69)
Renal/bladder cancer
14 (3.5%)
18 (4.5%)
0.77 (0.38, 1.57)
0.98 (0.41, 2.33)
Breast cancer
36 (9.0%)
50 (12.5%)
0.69 (0.44, 1.08)
0.83 (0.47, 1.46)
Lung cancer
23 (5.8%)
12 (3.0%)
2.0 (0.97, 4.02)
1.73 (0.77, 4.10)
Brain cancer
2 (0.5%)
4 (1.0%)
0.45 (0.09, 2.73)
NA
Endocrine cancer
13 (3.3%)
11 (2.8%)
1.28 (0.53, 2.68)
1.53 (0.60, 4.11)
Hematologic cancer
15 (3.8%)
24 (6.0%)
0.61 (0.31, 1.18)
0.59 (0.27, 1.25)
Melanoma/sarcoma
4 (1.0%)
14 (3.5%)
0.28 (0.09, 0.85)
0.19 (0.05, 0.59)
Gynecologic cancer
15 (3.7%)
20 (5.0%)
0.74 (0.37, 1.47)
0.57 (0.24, 1.26)
Prostate/testicular cancer
13 (3.2%)
16 (4%)
0.80 (0.38, 1.70)
0.49 (0.16, 1.50)
Other cancer
3 (0.8%)
2 (0.5%)
1.50 (0.25, 9.04)
NA
Note. The unadjusted and adjusted odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands (controls) are presented along with 95% confidence intervals for each malignancy. AOR: adjusted odds ratio; adjusted for age, sex, race, smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.
